...
首页> 外文期刊>Journal of pharmaceutical investigation >Spherical crystallization of ezetimibe for improvement in physicochemical and micromeritic properties
【24h】

Spherical crystallization of ezetimibe for improvement in physicochemical and micromeritic properties

机译:依泽替米贝的球状结晶,以改善其理化和微分子性能

获取原文
获取原文并翻译 | 示例
   

获取外文期刊封面封底 >>

       

摘要

Spherical agglomerates of ezetimibe (EZT) were prepared with hydrophilic polymers; polyvinyl pyrrolidone K30 (PVP) and/or poloxamer 188 (poloxamer) at drug to polymer ratios of 1:1 (w/w) by spherical crystallization technique, in order to improve its physicochemical and micromeritic properties. Three different bridging liquids; chloroform, dichloromethane and/or ethyl acetate along with good solvent acetone and poor solvent water were used to form six batches of agglomerates. Initial characterization of all batches in terms of micromeritic and physicochemical properties resulted in optimization of (A3, EZT:PVP:ethyl acetate) and (B3, EZT:poloxamer:ethyl acetate) batches and hence further investigated for drug-polymer interaction, crystallinity and morphology using FTIR, XRPD, DSC and SEM techniques. The results indicated presence of hydrogen bonding, crystallinity and spherical shape in agglomerates. Therefore, the optimized agglomerates (B3) were directly compressed into tablet. Unfortunately, drug release from the tablet was not satisfactory, suggesting a need of disintegrant from dissolution point of view. Therefore, these agglomerates were recompressed incorporating certain excipients and evaluated as per pharmacopoeia. The dissolution rate of prepared tablet was similar to that of marketed tablet (p > 0.05). It could be concluded that spherical crystallization could be one of the effective and alternative approaches for improved performance of EZT and its tablet formulation.
机译:用亲水性聚合物制备了依泽替米贝的球形团聚体(EZT)。聚乙烯吡咯烷酮K30(PVP)和/或泊洛沙姆188(泊洛沙姆)通过球形结晶技术以1:1(w / w)的药物与聚合物的比例,以改善其理化性质和微链性能。三种不同的桥接液体;使用氯仿,二氯甲烷和/或乙酸乙酯,再加上良好的溶剂丙酮和不良的溶剂水,形成六批附聚物。对所有批次的微球蛋白和理化性质进行初步表征导致优化了(A3,EZT:PVP:乙酸乙酯)和(B3,EZT:泊洛沙姆:乙酸乙酯)批次,因此进一步研究了药物-聚合物相互作用,结晶度和使用FTIR,XRPD,DSC和SEM技术进行形态学分析。结果表明在附聚物中存在氢键,结晶度和球形。因此,将优化的附聚物(B3)直接压制成片剂。不幸的是,从片剂中释放的药物不能令人满意,这表明从溶解的角度来看需要崩解剂。因此,将这些团聚体重新压入并掺入某些赋形剂,并按照药典进​​行评估。制得的片剂的溶出度与市售片剂的溶出度相似(p> 0.05)。可以得出结论,球形结晶可能是改善EZT及其片剂配方性能的有效方法和替代方法之一。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号